Atorvastatin ve Fenofibratın Birlikte Kullanımına Bağlı Gelişen Rabdomiyoliz ve Akut Böbrek Yetmezliği Olgusu
Abstract
Fibratlar ve statinler dislipidemi tedavisinde lipid düşürücü olarak kullanılan en etkili ilaçlardır. Genel olarak, bu ilaçların güvenli ve iyi tolere edildikleri düşünülmektedir. Fakat her iki ilaç ta akut böbrek hasarına yol açabilen rabdomiyoliz gibi ciddi yan etkilerle ilişkilidir. Burada kas ağrıları ile başvuran 50 yaşında bir erkek hastada, statin ve fibrat kombinasyonunun neden olduğu rabdomiyoliz ve akut böbrek hasarı olgusu sunuldu. Hasta destek tedavisi ile diyaliz ihtiyacı olmadan tam olarak iyileşti. Sonuç olarak, antihiperlipidemik ilaçların kullanımı yaygın olup, ölümcül olabilen yan etkilerinden dolayı bu ilaçların kullanımında ve özellikle de kombnasyonunda hastalar yakın takip edilmelidir.
Anahtar kelimeler: Atorvastatin, Fenofibrat, Rabdomiyoliz, Akut böbrek yetmezliği.
References
- Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
- Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atheroscle-rotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart As-sociation Task Force on Practice Guidelines. Circula-tion. 2013
- Kokko JP. Rhabdomyolysis. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 22nd ed. Philadelp-hia, Pa:WB Saunders 2004:649-51.
- Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician 2002;65:907-12.
- Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepide-miol Drug Saf 2007;16:352-8.
- Michal Tomaszewski, Karolina M. Stapien, Joanna Tomaszewska, Stanislaw J. Czuczwar. Statin-incduced myopathies. Pharmacol Rep 2011;63:859-866.
- Hansen KE,Hildebrand JP,Ferguson EE, Stein JH. Out-comes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165: 2671-6.
- Dormuth CR1, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P; Canadian Network for Observational Drug Effect Studies. Use of high potency statins and rates of admission for acute kidney injury: multicenter, ret-rospective observational analysis of administrative da-tabases. BMJ 2103;346:f880
- Graham DJ,Staffa JA,Shatin D,Andrade SE,Schech SD,LaGrenade L, et al. Incidence of hospitalized rhab-domyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
Year 2016,
Volume: 7 Issue: 26, 0 - 0, 30.06.2016
Abstract
References
- Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
- Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atheroscle-rotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart As-sociation Task Force on Practice Guidelines. Circula-tion. 2013
- Kokko JP. Rhabdomyolysis. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 22nd ed. Philadelp-hia, Pa:WB Saunders 2004:649-51.
- Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician 2002;65:907-12.
- Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepide-miol Drug Saf 2007;16:352-8.
- Michal Tomaszewski, Karolina M. Stapien, Joanna Tomaszewska, Stanislaw J. Czuczwar. Statin-incduced myopathies. Pharmacol Rep 2011;63:859-866.
- Hansen KE,Hildebrand JP,Ferguson EE, Stein JH. Out-comes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165: 2671-6.
- Dormuth CR1, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P; Canadian Network for Observational Drug Effect Studies. Use of high potency statins and rates of admission for acute kidney injury: multicenter, ret-rospective observational analysis of administrative da-tabases. BMJ 2103;346:f880
- Graham DJ,Staffa JA,Shatin D,Andrade SE,Schech SD,LaGrenade L, et al. Incidence of hospitalized rhab-domyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
There are 9 citations in total.
Details
| Journal Section | Case Report |
|---|---|
| Authors | |
| Publication Date | June 30, 2016 |
| Submission Date | June 16, 2015 |
| Published in Issue | Year 2016 Volume: 7 Issue: 26 |
